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RESEARCH
Skeletal muscle methylome 
and transcriptome integration reveals profound 
sex differences related to muscle function 
and substrate metabolism
Shanie Landen1, Macsue Jacques1, Danielle Hiam1,4, Javier Alvarez‑Romero1, Nicholas R. Harvey2,3, 
Larisa M. Haupt3, Lyn R. Griffiths3, Kevin J. Ashton2, Séverine Lamon4, Sarah Voisin1† and Nir Eynon1*†  
Abstract 
Nearly all human complex traits and diseases exhibit some degree of sex differences, with epigenetics being one of 
the main contributing factors. Various tissues display sex differences in DNA methylation; however, this has not yet 
been explored in skeletal muscle, despite skeletal muscle being among the tissues with the most transcriptomic sex 
differences. For the first time, we investigated the effect of sex on autosomal DNA methylation in human skeletal 
muscle across three independent cohorts (Gene SMART, FUSION, and GSE38291) using a meta‑analysis approach, 
totalling 369 human muscle samples (222 males and 147 females), and integrated this with known sex‑biased 
transcriptomics. We found 10,240 differentially methylated regions (DMRs) at FDR < 0.005, 94% of which were hypo‑
methylated in males, and gene set enrichment analysis revealed that differentially methylated genes were involved in 
muscle contraction and substrate metabolism. We then investigated biological factors underlying DNA methylation 
sex differences and found that circulating hormones were not associated with differential methylation at sex‑biased 
DNA methylation loci; however, these sex‑specific loci were enriched for binding sites of hormone‑related transcrip‑
tion factors (with top TFs including androgen (AR), estrogen (ESR1), and glucocorticoid (NR3C1) receptors). Fibre type 
proportions were associated with differential methylation across the genome, as well as across 16% of sex‑biased 
DNA methylation loci (FDR < 0.005). Integration of DNA methylomic results with transcriptomic data from the GTEx 
database and the FUSION cohort revealed 326 autosomal genes that display sex differences at both the epigenome 
and transcriptome levels. Importantly, transcriptional sex‑biased genes were overrepresented among epigenetic sex‑
biased genes (p value = 4.6e−13), suggesting differential DNA methylation and gene expression between male and 
female muscle are functionally linked. Finally, we validated expression of three genes with large effect sizes (FOXO3A, 
ALDH1A1, and GGT7) in the Gene SMART cohort with qPCR. GGT7, involved in antioxidant metabolism, displays male‑
biased expression as well as lower methylation in males across the three cohorts. In conclusion, we uncovered 8420 
genes that exhibit DNA methylation differences between males and females in human skeletal muscle that may 
modulate mechanisms controlling muscle metabolism and health.
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Introduction
Various diseases, including but not limited to muscular 
dystrophy, cardiomyopathies, and cardiovascular dis-
ease [1], display sex differences in prevalence, onset, 
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progression, or severity. To improve treatment for such 
diseases, it is crucial to uncover the molecular basis for 
the sex differences and their consequences on organ 
function [2]. Sexually differentiated traits and phenotypes 
stem from a combination of factors, including genetics 
(gene variants-by-sex interactions [3], XY chromosome 
complements [4–7], genomic imprinting [8]), the hormo-
nal milieu [9, 10], and gene regulation [11], with the latter 
likely contributing the most [1].
Recently, a large-scale study from the Genotype-Tis-
sue Expression (GTEx) consortium unravelled mRNA 
expression differences between the sexes that are not 
driven by sex chromosomes, across all tissues. Skeletal 
muscle was particularly divergent between the sexes, as 
gene expression profiles in this tissue could predict sex 
with high specificity and sensitivity [4]. These transcrip-
tomic differences underpin the numerous physiological 
differences in skeletal muscle between males and females, 
such as differences in substrate metabolism [12–14]. For 
example, females oxidize more lipids and less carbohy-
drates and amino acids during endurance exercise, and 
albeit depending on training status, tend to have a higher 
proportion of type I (slow-twitch) muscle fibres [15], 
all of which inherently contribute to enhanced fatigue-
resistance in female skeletal muscle [16]. As such, females 
exhibit higher mRNA and protein levels of lipid oxida-
tion-related genes than males [13]. Interestingly, the top 
gene set corresponding to sex-biased genes in the GTEx 
study corresponded to targets of the epigenetic writer 
polycomb repressive complex 2 (PRC2) and its associ-
ated epigenetic mark (H3K27me3) [4]. This suggests that 
the sex-specific deposition of epigenetic marks may be 
one of the sources of sex differences in gene expression. 
Epigenetics is a regulatory system that influences gene 
expression and is modulated by the genetic sequence 
and environmental stimuli [17]. DNA methylation is cur-
rently the best-characterized epigenetic modification and 
has been shown to differ between males and females in 
various tissues, such as pancreatic islets [18], blood [19, 
20], and more recently cultured myoblasts and myotubes 
[21]. While there is ample evidence for transcriptomic 
sex differences in skeletal muscle [4, 11, 12, 22–24], it is 
unclear whether sex differences exist in the DNA methyl-
ome of skeletal muscle tissue, and what factors contribute 
to these differences. Epigenome-wide association studies 
(EWAS) are ideal for investigating the impact of sex on 
genome-wide DNA methylation profiles.
Differences in skeletal muscle fibre-type proportions 
and circulating levels of sex hormones may contribute 
to epigenomic and transcriptomic differences between 
the sexes. Males and females are exposed to differing 
levels of sex hormones across the lifespan [25], which 
are primarily ascribed to the reproductive function, but 
their importance to non-reproductive functions, such 
as skeletal muscle [26], is becoming more apparent [27, 
28]. Sex steroid hormones engage through their specific 
ligand-receptors [4, 11, 29] and influence transcription 
and phenotype in a tissue- and sex-specific manner [9, 
30–33]. Not only can these receptors be differentially 
expressed between sexes [25], they also show sex-biased 
gene targeting patterns due to intrinsic differences in sex 
hormone levels [11, 34]. Human muscle consists of three 
distinct muscle fibre types: type I (slow-twitch oxidative), 
type IIa (fast-twitch oxidative), and type IIx (fast-twitch) 
fibres. Males tend to have a higher proportion of fast-
twitch type IIa muscle fibres in various muscle groups 
compared to females [35, 36]. The different fibre types 
exhibit different methylation patterns [37], as well as dif-
ferent contractile and metabolic properties [38]. Thus, 
differences in fibre type proportions may underlie sex dif-
ferences in skeletal muscle DNA methylation.
We performed a large-scale EWAS meta-analysis to 
explore sex differences in the DNA methylome of human 
skeletal muscle tissue, using three datasets from our own 
laboratory and open-access databases (n = 369 individu-
als; 217 males and 152 females). We established a list 
of sites (CpG) and regions showing DNA methylation 
differences between males and females, and explored 
their genomic context. We then investigated whether 
transcription factor binding, muscle fibre type distribu-
tion, and circulating sex hormone levels explained the 
observed sex differences in DNA methylation. Next, we 
integrated the sex-biased DNA methylation with known 
sex-biased mRNA expression from the GTEx consor-
tium, and inferred the potential downstream effects on 
skeletal muscle function. Lastly, we validated our findings 
with transcriptomic data from one cohort used in the 
meta-analysis and targeted qPCR from another cohort.
Results
Males show profound genome‑wide autosomal 
hypomethylation compared with females in human 
skeletal muscle
The DNA methylation meta-analysis was conducted on 
369 individuals from three datasets (217 males and 152 
females). We focused exclusively on the 22 autosomes as 
sex chromosomes represent a particular case whereby 
epigenetically driven X-chromosome inactivation takes 
place exclusively in females. All of the Gene SMART 
participants were apparently healthy, while the FUSION 
participants were either healthy or diagnosed with type 2 
diabetes mellitus (T2D), and the GSE38291 consisted of 
monozygotic twins discordant for T2D (Table 1).
We found 56,813 differentially methylated positions 
(DMPs, single CpG sites) between males and females, 
spread across the 22 autosomes, at a meta-analysis false 
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discovery rate (FDR) < 0.005 (Fig.  1, Additional file  3: 
Table  S2). Ninety-four percent of DMPs were hypo-
methylated in males compared with females (Fig.  1a). 
Henceforth throughout the text, “hypo-DMPs” and 
“hyper-DMPs” refer to positions which are differentially 
methylated in males compared to females. On aver-
age, DNA methylation levels differed by + 2.8% (hyper-
DMPs) and − 3.5% (hypo-DMPs) between males and 
females, with the largest effect sizes reaching + 15.2% and 
− 35.7%. To determine the degree to which sex explained 
the variability in DNA methylation at the sex-specific 
loci, we performed a principal component analysis (PCA) 
on these loci in each cohort independently, and ran a 
linear model between sex and the principal component 
(PC, also referred to as “dimension”) which visually dis-
tinguished sex (Fig.  1b; see “Methods”). Participants 
clustered according to sex when only focusing on the 
56,813 DMPs, suggesting that sex explained a substantial 
amount of variance at the DMPs. In the FUSION (PC1), 
Gene SMART (PC2), and GSE38291 (PC2) datasets, sex 
explained 30, 53, and 66% of variability in the relative PC 
at the sex-DMPs, respectively. Participants did not clus-
ter according to sex when looking at the whole methyl-
ome (Additional file  1: Figure S4), which is expected 
given that ~ 10% of the autosomal genome displayed sex-
specific DNA methylation.
Each data set had a unique study design that required 
considering different independent variables known to 
affect DNA methylation, such as age [39] and type 2 
diabetes (T2D) [40] in the analysis. We included each 
of these factors in the relevant linear models, but noted 
that sex was associated with T2D in the FUSION data-
set (Table  1), meaning that male participants from the 
FUSION cohort more commonly had T2D than females. 
Therefore, it is possible that the sex-related signal cap-
tured in this dataset was partially confounded by T2D. 
We repeated the meta-analysis excluding T2D partici-
pants from the FUSION cohort, but results remained 
unchanged (Additional file 1: Figure S7).
Fibre type proportions, but not circulating hormones, 
were associated with differential methylation at loci 
with sex‑specific DNA methylation
Males typically show a greater proportion of type II 
muscle fibres compared with females [15], and type 
II fibres exhibit hypomethylation compared to type 
I fibres [37]. Therefore, we hypothesized that the 
observed DNA methylation sex differences, specifically 
the hypomethylation in males, may be a result of differ-
ing fibre type distributions between males and females. 
We first estimated type I fibre proportions in the Gene 
SMART cohort via immunohistochemistry (Additional 
file  1: Figure S2D) and the FUSION cohort via RNA-
seq (data available for each dataset in Additional file 14: 
Table  S13). In both the Gene SMART and FUSION 
cohorts, females had higher proportions of type I 
fibres than males (Additional file 1: Figure S2B/C). We 
could not directly add fibre type proportions to the lin-
ear model as a covariate, since fibre type proportions 
are not a confounder (i.e. a factor that influences both 
Table 1 Characteristics of participants in each data set included in the DNA methylation meta‑analysis
Statistics shown for differences between males and females. The comparison of healthy and diabetic males and females tested whether males and females was 
equally represented in each group.
a Mean (SD); n (%)
b Welch two-sample t-test
FUSION Females, n =  115a Males, n =  159a p  valueb
Age (years) 61 (8) 59 (8) 0.2
Health 0.026
 Healthy 93 (81%) 109 (69%)
 T2D 22 (19%) 50 (31%)
Gene SMART Females, n =  20a Males, n =  45a p  valueb
Age (years) 35 (7) 32 (8) 0.1
Health
 Healthy 20 (100%) 45 (100%)
GSE38291 Females, n =  12a Males, n =  10a p  valueb
Age (years) 66 (9) 70 (4) 0.15
Health
 Healthy 6 (50%) 5 (50%)
 T2D 6 (50%) 5 (50%)
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sex and DNA methylation independently), but may 
be a direct downstream effect of sex, in turn affecting 
DNA methylation. Adding fibre type proportions in the 
model would therefore distort the association between 
sex and DNA methylation. To overcome this issue, we 
stratified the cohorts by sex, added fibre type propor-
tions to the model as a covariate and identified DNA 
methylation patterns associated with fibre type propor-
tions. We then meta-analysed the results to find CpGs 
robustly associated with fibre type proportions across 
both cohorts and all sexes (see “Methods”). We identi-
fied 16,275 CpGs associated with fibre type proportions 
(Additional file  1: Figure S2A). When restricting the 
analysis to the loci exhibiting sex-biased DNA methyla-
tion, 8805 (15.5%) of those were associated with fibre 
type proportions (FDR < 0.005). Effect sizes ranged 
from − 0.28% to + 0.30% DNA methylation difference 
per % increase in type I fibre content (Fig. 2a).
Fig. 1 Differentially methylated positions (DMPs) with sex in skeletal muscle. a Volcano plot of DNA methylation differences between males 
compared to females. Each point represents a tested CpG (633,645 in total) and those that appear in colour are DMPs at a meta‑analysis false 
discovery rate < 0.005; red DMPs are hypermethylated in males compared with females; blue DMPs are hypomethylated in males compared with 
females. The x‑axis represents the amount of DNA methylation difference between the sexes, and the y‑axis represents statistical significance 
(higher = more significant). Two DMPs that were present in all three studies and showed the largest effect size are labelled with the respective 
CpG and boxplots of β‑values from each study appear to the right (hyper‑DMP) and left (hypo‑DMP). b Principal component analysis plots of the 
methylation values at the DMPs; each point on the graph represents an individual; males denoted in green, females denoted in orange
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We then aimed to determine whether circulating sex 
hormone levels underlie the observed DNA methyla-
tion sex differences. We analysed estrogen (as estradiol, 
E2), testosterone (T), free testosterone (Free T), and 
sex-hormone binding globulin (SHBG) levels using mass 
spectrometry (Free T derived from calculation) of blood 
serum in males and females in the Gene SMART cohort. 
Males and females significantly differed in all four hor-
mone levels (Additional file 13: Table S12). To avoid col-
linearity with sex, we separated males and females for the 
association between sex-differential DNA methylation 
and circulating hormones. We assessed whether each of 
the four hormone levels was associated with DNA meth-
ylation across all of the CpGs and across the sex-DMPs 
in each sex by adjusting the linear model for a given hor-
mone. In both males and females, circulating free tes-
tosterone, testosterone, estrogen, and SHBG levels were 
not highly associated with DNA methylation (less than 
five DMPs; FDR < 0.005) of neither all of the CpGs tested 
nor the sex-DMPs previously identified (Additional file 1: 
Figure S3). To limit the potentially confounding effect of 
fluctuating ovarian hormone levels on DNA methylation, 
female muscle biopsies were collected in the early folli-
cular phase of the menstrual cycle (days 1–7) and blood 
serum was tested for follicle stimulating hormone (FSH), 
luteinizing hormone (LH), and progesterone (as well as 
E2 as previously mentioned). None of the four hormones 
(when adjusting for each hormone separately or when 
adjusting for the first two principal components; see 
‘methods’), were associated with differential methylation 
of all the CpGs or the sex-DMPs. This suggests that vari-
ations in ovarian hormone levels in the early follicular 
phase did not confound our results.
Males show profound genome‑wide autosomal 
hypomethylation compared with females in human 
skeletal muscle
Since the association between DNA methylation and 
gene expression depends on the genomic context, we 
inspected the genomic distribution of the DMPs to gain 
insights into their potential function [41]. We compared 
the distribution of hyper-, hypo-, and non-DMPs (CpGs 
included in the analysis which did not present sex-biased 
DNA methylation) among the various chromatin states 
in human skeletal muscle using the Roadmap Epigenom-
ics Project [42]. DMPs were not randomly distributed 
in the chromatin states (χ2 p value < 2.2 ×  10−16, Fig. 3a); 
specifically, hypo-DMPs were enriched in enhancers and 
depleted in transcription start sites (Additional file 1: Fig-
ure S1A), while hyper-DMPs were not enriched in any 
chromatin states given their scarcity. It should be noted 
that the Roadmap Epigenomics Project characterizes 
both male and female skeletal muscle chromatin states 
regions, and there are 536 regions across 369 unique 
genes where male and female chromatin states dif-
fer (across many tissues including skeletal muscle) [43]. 
Fig. 2 Fibre type‑related DNA methylation loci across sex‑biased DNA methylation loci. a Meta‑analysis effect size (x‑axis) and meta‑analysis 
significance (y‑axis) for the 56,813 tested sex‑biased CpGs. Hypomethylated (blue) and hypermethylated (red) point represent differentially 
methylated positions (DMPs) at false discovery rate (FDR) < 0.005. One hyper‑ and one hypo‑DMPs which showed the largest effect sizes are labelled 
with the respective CpG, with boxplots of β‑values per sex and scatter plots of β‑values relative to type I fibre proportion from the Gene SMART 
(b, c) and FUSION (e, f) cohorts. Females are represented in orange and males in green. d, g Forest plots for the given CpG, showing effect size and 
confidence intervals for each sex in each study
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Fig. 3 Genomic context of sex‑differentially methylated positions. a Distribution of hyper‑/hypo‑DMPs and non‑DMPs with respect to chromatin 
states (male skeletal muscle annotation). Blue is hypomethylated in males and red is hypermethylated in males. Red and blue add up to all of 
the sex‑DMPs. Black denotes the rest of the CpG sites from the analysis which are not DMPs. Asterisks represent a greater contribution to the 
significant relationship between DMP status and chromatin state (Additional file 1: Figure S1A). b Distribution of sex‑DMPs and non‑DMPs at loci 
whose chromatin states differ between male and female skeletal muscle. Purple denotes all DMPs (hypo and hyper combined) and black denotes 
non‑DMPs. c Distribution of sex‑DMPs and non‑DMPs in relation to CpG islands. Asterisks represent a greater contribution to the significant 
relationship between DMP status and CpG island location (Additional file 1: Figure S1B). d Bee swarm plot showing enrichment of transcription 
factor binding sites (TFBSs)(−(log10(p value) using Fisher’s exact tests) on the y‑axis for differentially methylated positions (DMPs) according to 
UniBind [45]. The names of the top 10 enriched TFs are denoted by the colour key; brown denotes non‑significant TFs. The various data sets for the 
same TFs are graphed with the corresponding colour
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Therefore, we performed the chromatin state enrichment 
analysis on both the male and female chromatin state 
annotation in skeletal muscle, which yielded equivalent 
findings. We noted that DMPs were overrepresented in 
loci whose chromatin states differ between males and 
females (38.7% of DMPs vs. 32.4% of non-DMPs are in 
chromatin states that differ between males and females), 
which means that the odds of a DMP being located in a 
sex-differing chromatin state increased by a factor of 
1.3 compared with a non-DMP (OR = 0.76, 95% confi-
dence interval = 0.75–0.77, Fisher test p value < 2.2e−16) 
(Fig. 3b). DMPs were also enriched in CpG island shores 
and depleted in CpG islands (χ2 p value < 2.2e−16) 
(Fig. 3c, Additional file 1: Figure S1B). DMPs were over-
represented among CpGs previously reported to be 
differentially methylated between male and female myo-
blasts (766 CpGs; p value < 0.0001) as well as myotubes 
(644 CpGs; p value < 0.0001) (see “Methods”).
Given the role of transcription factors (TFs) in regu-
lating chromatin accessibility and thus effecting down-
stream gene expression [44], as well as the recent studies 
identifying sex differences in TF targeting patterns [4, 
11], we next tested whether DMPs were enriched for the 
experimentally validated binding sites (TFBSs) of 268 
TFs from 518 different cell and tissue types [45, 46]. The 
DMPs were overrepresented in the binding sites of 41 
TFs (p value < 0.005, Fig. 3d, Additional file 15: Table S14), 
including hormone-related TFs such as androgen (AR), 
estrogen (ESR1), and glucocorticoid (NR3C1) receptors.
Gene set enrichment analysis of differentially methylated 
genes
We next performed Gene set enrichment analysis 
(GSEA) on the DMGs, as GSEA using epigenomic fea-
tures may reveal distinct enriched pathways that may 
not display gene expression differences [11, 43]. We 
performed GSEA on both the DMRs and DMPs (Fig. 4). 
GSEA on the DMRs revealed enrichment of several 
Gene Ontology (GO) terms, one Reactome pathway 
(“muscle contraction”), but no Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways (Additional 
file 11: Table S10) (FDR < 0.005). However, GSEA on the 
DMPs revealed enrichment across all three databases 
(Additional file  6: Table  S5, Additional file  8: Table  S7 
and Additional file 10: Table S9). Most of the enriched 
GO terms are biological process (BP) terms, many of 
which relate to anatomical structure development as 
well as many muscle-related processes. Furthermore, 
DMPs were enriched for GO terms related to substrate 
metabolism such as lipid, protein, and carbohydrate 
derivative metabolic processes. Nine-hundred and 
twenty-five genes of the 1407 genes involved in KEGG 
metabolic pathways were differentially methylated, 
representing many aspects of substrate metabolism, 
although the pathway was only significant when analys-
ing the DMPs.
Genes with sex‑biased methylation exhibit sex‑biased DNA 
expression in human skeletal muscle
Differentially methylated genes (DMGs) were deter-
mined by identifying the genes annotated to differen-
tially methylated regions (DMRs), as DMRs remove 
spatial redundancy (CpG sites ~ 500 base pairs apart 
are typically highly correlated [47]), and may provide 
more robust and functionally important informa-
tion than DMPs [48, 49]. We identified 10,240 DMRs 
(Stouffer, harmonic mean of the individual component 
FDRs (HMFDR), and Fisher p value < 0.005). These 
DMRs were annotated to 8420 unique autosomal genes 
(including non-coding genes) as annotated by Zhou 
et al. [50] (see “Methods”; Additional file 4: Table S3).
To gain insights into the potential downstream effects 
of sex-biased DNA methylation on gene expression, we 
integrated results from the EWAS meta-analysis of sex 
with genes whose mRNA expression levels are known to 
differ between males and females. We used version 8 of 
the Genotype-Tissue Expression (GTEx) database which 
contains 803 RNA-sequencing profiles in human skeletal 
muscle (n = 543 males and n = 260 females). There were 
2689 sex-differentially expressed genes (DEGs) on the 
autosomes in skeletal muscle (accessed from GTEx portal 
on 08/26/2020). Of the 2689 DEGs, 973 (~ 36%) were in 
common with DMGs from our cohorts (Fig. 5, Additional 
file  3: Table  S2), including the gene Gamma-Glutamyl-
transferase 7 (GGT7) (Fig.  6). We confirmed an enrich-
ment of DMRs across sex-biased genes (hypergeometric 
test p value = 4.6 ×  10−13), suggesting that the overlap 
between sex-differentially methylated genes and sex-dif-
ferentially expressed genes is larger than what would be 
expected by chance alone. To gain insight on the relation-
ship between DNA methylation and gene expression of 
sex-biased genes, we assessed the direction of correla-
tion between DMRs that are annotated to either pro-
moter (TssA and TssAFlnk) or enhancer (Enh and EnhG) 
regions and their given gene expression (Fig. 5c, d). Sixty-
two and 59% of DMRs in promoter and enhancer regions, 
respectively, were inversely correlated with gene expres-
sion. (From GTEx transcriptome data, similar results 
were yielded with the FUSION transcriptome data.) The 
inverse correlation between DNA methylation at both 
promoter and enhancer regions with gene expression was 
more than would be expected to occur by random chance 
(10,000 random permutations; p value < 0.0001 and p 
value = 0.0009, respectively; Additional file 1: Figure S5).
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Fig. 4 Gene set enrichment analysis of the differentially methylated genes. a Top enriched Gene Ontology (GO) terms, Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathways, and Reactome pathways from GSEA of DMRs and DMPs. Columns represent (1) name (2) number 
of significant/total number of genes (3) false discovery rate (FDR) of over‑representation of term or pathway. Full list of terms and pathways in 
Additional file 6: Table S5, Additional file 7: Table S6, Additional file 8: Table S7, Additional file 9: Table S8, Additional file 10: Table S9, Additional file 11: 
Table S10. b Sankey diagram of muscle contraction‑related pathways across the three GSEA databases tested and genes within those pathways 
that were both differentially methylated and expressed (in GTEx and FUSION) between males and females. Numbers next to pathways denote 
the number of enriched genes in the pathway; numbers next to genes denote the number of pathways (from the ones displayed) that the gene 
belongs to. Diagram created using SankeyMATIC
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Validation of GTEx sex‑biased genes in the cohorts used 
for methylation analysis
We sought to validate the sex-biased gene expression 
obtained from GTEx in a subset of the samples used for 
methylation analysis since the DMGs and DEGs analy-
ses were obtained from different muscle groups. (The 
DMGs of the current study are from the vastus later-
alis, while the GTEx DEGs are from the gastrocnemius.) 
Fig. 5 Integration of differentially methylated genes and differentially expressed genes. a Venn diagram of the overlap between differentially 
methylated genes (DMGs; derived from DMRs), differentially expressed genes derived from GTEx (DEGs GTEx), and differentially expressed genes 
derived from FUSION (DEGs FUSION) between males and females. b Subset of 12 genes with consistently large effect sizes or of biological relevance 
to skeletal muscle. c Correlation between the effect sizes of DMRs in enhancer regions and the effect sizes of gene expression of the relative 
annotated gene (for GTEx sex‑biased genes). Quadrant percentages indicate the percentage DMRs/DEGs that fall into each quadrant. d Correlation 
between the effect sizes of DMRs in promoter regions and the effect sizes of gene expression of the relative annotated gene (for GTEx sex‑biased 
genes). Quadrant percentages indicate the percentage DMRs/DEGs that fall into each quadrant
(See figure on next page.)
Fig. 6 Differential DNA methylation and expression of GGT7 between males and females. a UCSC gene track of GGT7. From top to bottom: base pair 
scale in black, GENCODE gene tracks transcript variants in blue, GeneHancer regulatory element annotations in light blue, hyper‑DMRs tracks in red, 
hypo‑DMRs tracks in blue. b Heatmap of the Gene SMART study (beta values adjusted for all confounders except sex) across the 3 CpGs included 
in the GGT7 hypo‑DMR selected in blue lines and labelled with mean DMR effect size (n = 65). Each row represents an individual; green denotes 
males and orange denotes females; ordered by similarity to other individuals. Each column corresponds to a CpG in the DMR, ordered by genomic 
location and corresponding to 5C. Blue denotes hypomethylation; red denotes hypermethylation. c Distribution of DNA methylation (beta values) 
in males and females, for the three CpGs in the DMR, matching 5B (n = 65). d GGT7 RNAseq expression (TPM—transcripts per million) in males 
and females of the GTEx ( adapted from GTEx portal, n = 803). e GGT7 RNAseq expression in the FUSION males and females (FPKM—fragments 
per kilobase of transcript per million) (n = 274). f GGT7 qPCR expression in a subset of Gene SMART males and females (AU—arbitrary units;  2−∆Ct) 
(n = 30)
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Fig. 6 (See legend on previous page.)
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Although both are skeletal muscle tissue from the leg, 
there may be differences in muscle phenotypes in dif-
fering muscle groups [51]. Analysis of RNA sequencing 
data from the FUSION cohort revealed 3751 autosomal 
genes with sex-biased expression (FDR < 0.005). The FDR 
threshold we chose for the FUSION gene expression data 
was more stringent than the GTEx local false sign rate 
threshold (lfsr < 0.05), yet, ~ 34% of the genes which were 
both DEGs in GTEx and DMGs were also DEGs in the 
FUSION cohort, totalling 326 genes (hereinto referred 
to as ‘overlapping genes’) (Fig.  5a). Given that both the 
GTEx and FUSION cohorts include participants of rela-
tively older ages, we sought to confirm the mRNA levels 
in the younger cohort in the analysis (the Gene SMART) 
for three genes that displayed sex differences at both the 
mRNA and DNA methylation levels (GGT7, FOXO3, and 
ALDH1A1) (Table 2, Additional file 12: Table S11, Addi-
tional file 1: Figure S6).
DNA methylation and gene expression of GGT7, FOXO3 
and ALDH1A1 consistently differ between males 
and females in human skeletal muscle
Three-hundred twenty-six genes exhibited differential 
methylation in the meta-analysis and differential expres-
sion among the GTEx and FUSION cohorts, termed 
‘overlapping genes’. Of those genes, we tested three 
for gene expression levels, GGT7, Forkhead Box O3 
(FOXO3), and Aldehyde Dehydrogenase 1 Family Mem-
ber A1 (ALDH1A1), in the younger cohort included in 
the DNA methylation analysis (Gene SMART) given 
the effect that age has on skeletal muscle gene expres-
sion [52]. These three genes showed a large effect size in 
gene expression and DNA methylation, displayed mod-
erate gene expression levels in skeletal muscle relative 
to other tissues, and/or contained numerous DMPs and 
DMRs (Table  2). The direction of sex-biased expression 
was consistent for GGT7 and ALDH1A1 across GTEx, 
FUSION, and Gene SMART cohorts (GGT7: GTEx 
lfsr < 2.2e−16, FUSION FDR = 1.3e−45, Gene SMART p 
value = 0.0003; ALDH1A1: GTEx lfsr < 2.2e−16; FUSION 
FDR = 2.3e−8, Gene SMART p value = 0.001), while the 
direction was opposite for FOXO3 (FUSION and GTEx 
FOXO3 expression lower in males, Gene SMART FOXO3 
expression higher in males (GTEx lfsr = 0.01, FUSION 
FDR = 0.001, Gene SMART p value = 0.0008)). As a 
specific example of the extent of sex differences across 
the different layers of analysis, GGT7 displays male-
biased expression in skeletal muscle (GTEx lfsr < 2.2e−16; 
FUSION FDR = 1.3e−45, Gene SMART p value = 0.0003) 
as well as lower methylation in males at DMPs and DMRs 
annotated to GGT7 (max DMR: Fisher p value < 0.00−15, 
max beta value effect size = −28.5%, mean beta value 
effect size = −20.4%) (Fig. 6).
Discussion
We conducted a large-scale meta-analysis of DNA meth-
ylation differences between males and females in skeletal 
muscle, and integrated them with transcriptomic data. 
We revealed that males display profound genome-wide 
hypomethylation compared with females, and that hor-
mone-related TFBSs and muscle fibre type proportions 
underlie the observed DNA methylation sex differences. 
We also showed that many sex-biased genes found in 
GTEx exhibit sex-biased DNA methylation, which was 
partially confirmed in the FUSION cohort. We then vali-
dated the gene expression (qPCR) levels of three genes 
with large DNA methylation and expression differences 
between the sexes across cohorts, and confirmed that 
GGT7 and ALDH1A1 had higher gene expression in 
males. Finally, we showed that the DMGs are overwhelm-
ingly involved in muscle contraction, as well as substrate 
metabolism and anatomical structure-related pathways.
In the present study, the overwhelming majority (94%) 
of the DMPs were hypomethylated in males. Interest-
ingly, global autosomal hypomethylation in males has 
been observed in various other tissues [53], including 
blood [54, 55] and pancreatic islets [18]. We aimed to 
uncover some of the biological mechanisms at the root 
of these epigenetic sex-differences by assessing the con-
tributions of fibre type proportions and sex hormone lev-
els to the observed DNA methylation sex differences. We 
hypothesized that differences in fibre type proportions 
between sexes may partly explain our findings [55–57], 
as studies report that type I fibres are hypermethylated 
compared with type II fibres [37], and as females tend 
to have a higher proportion of type I fibres than males 
[15]. Consistent with this, we observed that females had 
higher proportions of type I muscle fibres than males and 
that type I fibre content was mostly associated with DNA 
Table 2 Gene expression and DNA methylation differences 
between males and females for three genes across the cohorts 
used in the analysis
Gene expression effect size in males 
compared to females
Mean effect 
size of DMR 
showing 
largest effect 














GGT7 0.81 1.6 3.5 − 20.4
FOXO3 − 0.04 − 0.2 3.0 − 1.9
ALDH1A1 0.33 0.4 2.8 − 10
Page 12 of 20Landen et al. Clin Epigenet          (2021) 13:202 
hypermethylation. Importantly, 16% of the loci exhibit-
ing sex-biased DNA methylation were also associated 
with fibre type proportions. This suggests that at those 
CpGs, differences in DNA methylation between the sexes 
are due to the inherent sex differences in fibre type pro-
portions. Nonetheless, the vast majority of the loci that 
exhibit sex-biased DNA methylation (84%; 48,008 CpGs) 
differ regardless of the sex differences in fibre type pro-
portions. A recent study on the FUSION cohort, adjusted 
for fibre type proportions, found that it explains a sub-
stantial portion of the variability in DNA methylation 
for many metabolic phenotypes of interest [58]. Skel-
etal muscle DNA methylation analyses are performed on 
whole muscle due to the cost and technical limitations 
of isolating muscle cell types. Differing non-muscle cell 
types may be present in a muscle biopsy sample, and it 
is currently unknown how much of the muscle DNA 
methylation profile may actually be representing other 
cell types [59–61]. Bioinformatics deconvolution meth-
ods have not yet been developed for bulk skeletal muscle 
DNA methylation. Considering that the DNA methyla-
tion differences between cell types are large [62], future 
studies should aim at determining DNA methylation pat-
terns of the different muscle fibre and cell types so that 
bulk muscle DNA methylation data can be adjusted for 
the appropriate cell and fibre proportions.
None of the circulating sex hormones were associated 
with differential methylation across all CpGs, nor across 
the sex-DMPs in males or females. However, the range of 
each hormone within each sex may not be large enough 
to draw out the effect of varying levels of each hormone 
on the methylome. In the current study, hormone levels 
were measured from blood, while DNA methylation was 
measured from skeletal muscle. DNA methylation pat-
terns are highly tissue-specific [63, 64], and sex hormone 
levels in the circulation are not necessarily correlated 
with those intramuscularly. Moreover, intramuscular, and 
not circulating, sex hormone levels may be correlated 
with muscular function [65, 66]. A recent review empha-
sizes the importance of measuring intramuscular sex 
hormone levels when assessing muscle-related properties 
in females [67].
The enrichment of hormone-related TFBS among the 
sex-DMPs suggests that lifelong exposure to differing 
hormone levels significantly contributes to the observed 
sex differences in skeletal muscle DNA methylation. 
Although, the alternative is possible, in which DNA 
methylation differences influence sex hormone levels. In 
Unibind, ChIP-seq data in skeletal muscle were limited to 
one TF (CTCF), so the enrichment of TFBSs among sex 
DMPs may have limited functional significance in skel-
etal muscle. Nonetheless, many of the TFs that showed 
strong enrichment in the present study, such as AR [68, 
69], ESR1 [69], and SMAD3 [70], are expressed in skeletal 
muscle and have important roles in muscle phenotype. 
Of note, multiple testing assumptions cannot be met 
with Unibind; therefore, no correction can be made, and 
therefore, false positives may emerge. Two recent studies 
leveraging the GTEx database identified sex differences 
in TF targeting patterns across several human tissues, 
including skeletal muscle, which contribute to sex-biased 
gene regulatory networks [11] and gene expression [4]. 
Differences in sex hormone levels between developing 
males and females are already evident in utero [71], mak-
ing it challenging to design an experiment in humans that 
disentangles the effect of long-term hormonal exposure 
from biological sex, and other related factors, on cell 
function. Studies have utilized menopausal females [72] 
and transgender people [73] receiving hormone replace-
ment therapy (HRT) to investigate the influence of long-
term exposure to sex hormones on various phenotypes 
and risk of diseases. For example, HRT for one postmen-
opausal monozygotic twin and not the other has positive 
effects on regulation of muscle contraction and myo-
nuclei organization, suggesting that estrogen has direct 
effects on muscle function [74]. Nevertheless, uncovering 
the genomic regions that display sex-differential methyla-
tion as well as contain hormone-responsive TFBSs, pro-
vides insight on which genomic regions, hormones, and 
TFs are discerning male and female skeletal muscle.
The enrichment for muscle contraction-related path-
ways among the DMGs across GO, KEGG, and Reactome 
suggests that the sex-differential DNA methylation has 
functional relevance in skeletal muscle function. Fur-
thermore, enrichment of substrate metabolism pathways 
among the DMGs suggests that the observed sex differ-
ences in carbohydrate, lipid, and protein metabolism [13, 
75] may have a molecular, more specifically an epigenetic, 
basis. This is corroborated with results from transcrip-
tomic studies, which report that skeletal muscle female-
biased genes are enriched for pathways involved in fatty 
acid metabolism, while male-biased genes are enriched 
for pathways involved in protein catabolism [22].
Although not well understood, the sex chromosome 
complement may also influence autosomal DNA meth-
ylation patterns. In cultured fibroblasts, the presence 
of Sex-determining Region Y (SRY) is associated with 
lower autosomal methylation levels [76–78]. Addition-
ally, a higher number of the X chromosomes, in the 
absence of SRY, leads to increased methylation levels at 
a specific sex-differentially methylated autosomal region 
[78]. This could be attributed to allele dosage compensa-
tion, a female-specific process that silences one of the X 
chromosomes in a cell [79, 80]. Approximately one-third 
of genes ‘escape’ inactivation, remain transcriptionally 
active in XX cells, [80–82], and have been suggested to 
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affect autosomal DNA methylation via their histone 
marks [78, 83]. Moreover, females with Turner syndrome 
(partially/fully missing one X) and monosomy X have 
lower global methylation than XX females, but higher 
than XY males [84, 85]. The effect of sex chromosome 
complement on autosomal DNA methylation in skeletal 
muscle has yet to be explored. Finally, genetic variants 
(copy number variants (CNVs) and single nucleotide pol-
ymorphisms (SNPs)) may affect DNA methylation status 
at specific loci [86], termed methylation-quantitative trait 
loci (meQTL). However, with the exception of a female 
bias for large, rare CNVs, there are no large sex differ-
ences in autosomal SNP minor allele frequencies [1].
The relationship between DNA methylation and gene 
expression is complex; DNA methylation at promoters, 
enhancers, and  1st exons is generally believed to enhance 
gene silencing, while DNA methylation at gene bodies 
can sometimes be associated with increased gene expres-
sion [87–91]. Using a permutation test, we showed that 
DNA methylation differences between the sexes at pro-
moters and enhancers were more often associated with 
lower gene expression than would be expected by chance 
alone. DNA methylation differences between the sexes 
were also particularly prominent in chromatin states 
that are known differ between males and females. This 
suggests that DNA methylation differences between 
males and females reflect alterations in chromatin activ-
ity, and differential epigenetic states and expression are 
likely functionally connected. In line with this, chroma-
tin states that differ between the sexes have been shown 
to be enriched for sex-biased genes across various tis-
sues, including skeletal muscle [43]. However, it is not 
yet possible to assess whether the relationship reflects 
correlation or direct causality. There is still debate around 
whether epigenomic features drive regulatory processes 
or are merely a consequence of transcription factor bind-
ing [43].
We identified 326 genes with consistent differential skel-
etal muscle DNA methylation and expression across 1172 
individuals altogether (369 individuals from three cohorts 
for DNA methylation and 1077 individuals from two 
cohorts for gene expression). Although we found profound 
global DNA hypomethylation in males, of the overlap-
ping genes there were equivalent numbers of genes over- 
and under-expressed in males compared with females 
for both GTEx and FUSION. Indeed, hypermethylation 
is not always associated with decreased gene expression 
[92]. The substantial overlap between differentially meth-
ylated genes and differentially expressed genes highlights 
many genes that may be of interest for their roles in mus-
cle-related processes. Furthermore, the significant over-
lap between the present study and Davegårdh et  al. [21] 
implies that there are specific loci and genes that show 
DNA methylation differences between the sexes both in 
muscle cells and in muscle tissue. We focused on three of 
these genes that displayed a large DNA methylation differ-
ence between males and females, are highly expressed in 
skeletal muscle, or play a role in skeletal muscle function: 
FOXO3 for its role in ageing, longevity, and regulating the 
cell cycle [93]; ALDH1A1 for its role in aldehyde oxida-
tion and because sex differences in skeletal muscle mRNA 
levels have been reported, suggesting that males might be 
able to metabolize aldehydes (i.e. alcohol) more efficiently 
than females [12]; and GGT7 for its role in antioxidant 
activity [94]. Of these three genes (which were validated 
across GTEx, FUSION, and Gene SMART), FOXO3 and 
GGT7 have also been reported to exhibit differential 
methylation between male and female myoblasts as well as 
myotubes [21]. GGT7 and ALDH1A1 showed consistently 
higher expression levels in males, while FOXO3 showed 
opposite sex-biased expression in the young versus the 
old cohorts. FOXO3 expression was lower in males in the 
older cohorts (GTEx and FUSION), and higher in males 
in the younger cohort (Gene SMART). Other studies have 
shown that males have higher FOXO3 expression in young 
skeletal muscle [95] and that elderly females have higher 
skeletal muscle FOXO3 expression than younger females 
[96]. While FOXO3 skeletal muscle gene expression differs 
between males and females, it seems that the direction is 
opposite in young and old individuals, which emphasizes 
the caution that should be used when interpreting sex dif-
ferences across a large age range of individuals. Interest-
ingly, FOXO3 was hypomethylated in skeletal muscle with 
age in a recent study from our group [97]. Regions with 
differential DNA methylation in the three validated genes 
were located in enhancers (FOXO3 and ALDH1A1) and 
regions of strong transcription (GGT7), suggesting that 
subsequent transcription may be altered. As an example, 
the promoter,  1st exon, and gene body of GGT7 were hypo-
methylated in males and males had higher GGT7 expres-
sion. GGT7 is highly expressed in skeletal muscle and 
metabolises glutathione, which is a ubiquitous “master 
antioxidant” that contributes to cellular homeostasis [98].
In conclusion, we showed that the DNA methylation 
of hundreds of genes differs between male and female 
human skeletal muscle. We uncovered important bio-
logical factors underlying sex-specific skeletal muscle 
DNA methylation. Integration of the DNA methylome 
and transcriptome, as well as gene expression valida-
tion, identifies sex-specific genes associated with mus-
cle metabolism and function. Uncovering the molecular 
basis of sex differences across different tissues will aid 
in the characterization of muscle phenotypes in health 
and disease. The effects of other upstream drivers on 
sex differences in the muscle methylome, such as non-
muscle cell type, the XY chromosomes, and genetic 
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variants still need to be explored. Molecular mecha-
nisms that display sex differences in skeletal mus-




We conducted a meta-analysis of three independent epi-
genome-wide association studies (EWAS) of sex includ-
ing the Gene Skeletal Muscle Adaptive Response to 
Training (SMART) study from our laboratory [99], the 
Finland–United States Investigation of NIDDM Genetics 
(FUSION) study from the dbGAP repository (phs000867.
v1.p1) [58], and the GSE38291 dataset from the Gene 
Expression Omnibus (GEO) platform [100]. Detailed 
participant characteristics, study design, muscle collec-
tion, data pre-processing, and data analysis specifications 
for each study are in Additional file 2: Table S1. Briefly, all 
studies performed biopsies on the vastus lateralis mus-
cle, all participants were of Caucasian descent (except 
1 individual of mixed Caucasian/aboriginal decent), 
and included either healthy or healthy and T2D indi-
viduals aged 18–80  years. The Gene SMART study was 
approved by the Victoria University Human Ethics Com-
mittee (HRE13-223), and written informed consent was 
obtained from each participant. NIH has approved our 
request [#96795-2] for the dataset general research use in 
the FUSION tissue biopsy study.
DNA extraction and methylation method‑ gene SMART 
study samples
Genomic DNA was extracted from the samples using 
the AllPrep DNA/RNA Mini Kit (Qiagen, 80204) follow-
ing the user manual guidelines. Global DNA methylation 
profiling was generated with the Infinium MethylationE-
PIC BeadChip Kit (Queensland University of Technol-
ogy and Diagenode, Austria). The first set was analysed 
in 2017 and contained samples (n = 50) from 25 males 
which were scrambled on the chips to ensure that time-
point and age were not confounded with batch and chip 
positioning in the array. The second set was analysed in 
2019 and contained samples (n = 80) from 20 males and 
20 females which were scrambled on the chips to ensure 
that timepoint, sex, and age were not confounded with 
batch and chip positioning in the array. The genome-wide 
DNA methylation pattern was analysed with the Infinium 
MethylationEPIC BeadChip array.
Bioinformatics and statistical analysis of DNA methylation
Pre‑processing
The pre-processing of DNA methylation data was 
performed according to the bioinformatics pipeline 
developed for the Bioconductor project [101]. Raw meth-
ylation data were pre-processed, filtered and normal-
ized across samples. Probes that had a detection p value 
of > 0.01, located on X and Y chromosomes or cross-
hybridizing, or related to a SNP frequent in European 
populations, were removed. It is important to note that 
the list of cross-hybridizing probes was supplied manu-
ally [102] as the list supplied to the ChAMP package was 
outdated. Specifically, there are thousands of probes in 
the Illumina microarrays that cross-hybridize with the 
X-chromosome and may lead to false discovery of auto-
somal sex-associated DNA methylation [103]. The BMIQ 
algorithm was used to correct for the Infinium type I and 
type II probe bias. β-values were corrected for both batch 
and position in the batch using ComBat [104].
Statistical analysis
We adjusted each EWAS for bias and inflation using the 
empirical null distribution as implemented in BACON 
[105]. Inflation and bias in EWAS are caused by unmeas-
ured technical and biological confounding, such as 
population substructure, batch effects, and cellular het-
erogeneity [106]. The inflation factor is higher when the 
expected number of true associations is high (as it is for 
age); it is also greater for studies with higher statistical 
power [105]. The results were consistent with the infla-
tion factors and biases reported in an EWAS of age in 
blood [105]. Smaller cohorts were weighed less in the 
meta-analysis than bigger cohorts as the pooled esti-
mates are based on standard  error  (which takes sample 
size into account). Results from the independent EWAS 
were combined using an inverse variance weighted meta-
analysis with METAL [107]. We used METAL since it 
does not require all DNA methylation datasets to include 
every CpG site on the HumanMethylation arrays. Given 
that the FUSION and Gene SMART datasets were ana-
lysed with the EPIC array, while the GSE38291 dataset 
was analysed with the 27  K array, there are a substan-
tial number of probes with data available only from the 
FUSION and Gene SMART studies. For robustness, we 
only included CpGs present in at least two of the three 
cohorts after pre-processing (633,645 CpGs). We used 
a fixed effects (as opposed to random effects) meta-
analysis, assuming one true effect size of sex on DNA 
methylation, which is shared by all the included studies. 
Nevertheless, Cochran’s Q-test for heterogeneity was 
performed to test whether effect sizes were homogene-
ous between studies (a heterogeneity index (I2) > 50% 
reflects heterogeneity between studies). We noted one 
sample from the FUSION cohort had a discordant sex 
prediction, using the getSex function from minfi [108], 
and reran analyses without that sample but obtained 
identical pathways and differentially methylated genes.
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To identify DMPs, we used linear models as imple-
mented in the limma package in R [109], using the par-
ticipants’ ID as a blocking variable to account for the 
repeated measures design (for twin (GSE38291) and 
duplicate samples (Gene SMART), using DuplicateCor-
relation). The main sources of variability in methylation 
varied depending on the cohort and were included as 
independent variables in the linear model accordingly. 
For the Gene SMART study, the linear model was of 
the form:
Timepoint: before and after four weeks of high-
intensity interval training
Analysis set: one set analysed in 2017 and one in 
2019
For the FUSION study, the linear model was of the 
form:
For the GSE38291 study, the linear model was of the 
form:
All results were adjusted for multiple testing using 
the Benjamini and Hochberg correction [110], and all 
CpGs showing an FDR < 0.005 were considered sig-
nificant [111]. DMRs were identified using the DMR-
cate package with default settings [112]. DMRs with 
Stouffer, Fisher, and harmonic mean of the individual 
component FDRs (HMFDR) statistics < 0.005 were 
deemed significant. Effect sizes are reported as mean 
differences in DNA methylation (%) between the sexes. 
PCAs were analysed using the package factoMiner, and 
were performed separately per cohort given that tech-
nical variability substantially contributes to variabil-
ity in DNA methylation. The percentage reported in 
which sex explains the variability in DNA methylation 
at DMPs was determined by extracting the adjusted  R2 
from the linear model: PC ~ sex; the PC which visually 
distinguished males and females in the PCA in each 
cohort was used in the linear model. To assess whether 
fibre type proportions differ between males and females 
in the Gene SMART and FUSION cohorts, we used a 
beta regression model [113] using the betareg package 
in R. We then included type I fibre ratio as a covariate 
in the linear models. To investigate whether circulating 
hormones is associated with DNA methylation of the 
sex-DMPs, we included each sex hormone as a covari-
ate in a linear model, separately. One male from the 
DNAm ∼ sex ∗ timepoint+ age+ analysis set
DNAm ∼ sex + BMI + smoking status
+ oral glucose tolerance test status
DNAm ∼ sex+ age+ diabetes status
Gene SMART cohort had missing circulating hormone 
values; and one two females from the Gene SMART 
cohort had missing type I fibre proportions. For these 
three individuals, missing values were imputed with the 
mice package in R [114].
To annotate the CpGs to the genome (see “Availability 
of Data and Materials”), we integrated a comprehensive 
annotation of Illumina HumanMethylation arrays [50] 
with chromatin states from the Roadmap Epigenom-
ics Project [42] and the latest GeneHancer information 
[115]. DMGs were determined by the annotations of 
the DMRs. For chromatin state enrichment, DMPs that 
were annotated to two differing chromatin states were 
removed for simplicity and because there were very few 
such DMPs. GSEA on KEGG and GO databases was 
performed on DMRs and DMPs using the goregion and 
gometh (gsameth for Reactome) functions in the missMe-
thyl R package [116] 117. All analyses were performed 
using the R software version 4.0.3.
Enrichment of TFBSs among the identified DMPs was 
performed using the enrichment analysis tool in http:// 
unibi nd. uio. no/ which utilizes the runLOLA function of 
the R package LOLA [46]. The analysis type selected was 
enrichment with background; and background provided 
included all tested CpGs. Analysis using CpGs in DMRs 
versus DMPs yielded similar results. The outputted p 
value is reported; without applying an FDR correction 
since many TFBS datasets are not independent so the 
assumptions behind the FDR correction cannot be met. 
TFs from all tissues were included as only one TF, to date, 
has been validated among skeletal muscle tissues or cells.
To assess whether sex-DMPs were over-represented 
among CpGs which have been reported to be differen-
tially methylated in male and female myoblasts and myo-
tubes [21], we first overlapped the sex-DMPs with CpGs 
with sex-differential DNA methylation in myoblasts. We 
then randomly sampled the same number of CpGs which 
were differentially methylated in myoblasts from the total 
CpGs in the 450  K array, as this was the Illumina array 
used for the study, and overlapped those randomly sam-
pled CpGs with the sex-DMPs. We performed this ran-
dom sampling 10,000 times to obtain a p value signifying 
whether the amount of overlap between the two studies 
could have occurred by chance. We then repeated this 
same method for the myotubes.
Fibre types: meta‑analysis and derivation 
from immunohistochemistry and RNA‑seq
Myosin heavy chain is currently the best available 
marker for fibre typing [118]. Gene SMART muscle 
sections were frozen in optimum-cutting temperature 
(OCT) medium by holding the sample with OCT in 
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liquid-nitrogen cooled isopentane until frozen. Samples 
were stored in − 80 °C until they were sectioned at 8 µM 
with a cryostat. The IHC protocol was performed as is 
described elsewhere [119]. Briefly, sections were blocked 
in 4% goat serum (Life Technologies). Primary antibodies 
BA-F8 (MHCI), BF-35 (MHCIIA), and 6H1 (MHCIIX) 
were purchased from DSHB, Iowa. Secondary antibod-
ies goat anti-mouse IgG2b 350, goat anti-mouse IgG1 
488, and goat anti-mouse IgM 555 were purchased from 
Invitrogen. Some samples were fixed in paraformalde-
hyde for other analyses, and for those samples, an anti-
gen-retrieval protocol consisting of a 10-min incubation 
at 50  °C of Proteinase K diluted in MilliQ (1:1000) and 
subsequent 1-min washes was performed before the IHC. 
Imaging was performed on the Olympus BX51.
To determine type I fibre proportions in the FUSION 
cohort, we followed the validated method as performed 
by the original study on the FUSION cohort [58]. Briefly, 
we derived type I fibre proportions from the RNA-seq 
expression data (TPMs) for type I (MYH7), type IIA 
(MYH2), and type IIX (MYH1). We calculated the ratio 
of MYH7 out of the total. We then included this ratio in 
the + FT linear model.
To determine whether the inherent sex differences 
in fibre type proportions underlie the sex differences in 
DNA methylation, we separated the males and females of 
the Gene SMART and FUSION cohorts and performed 
a meta-analysis on the four groups (FUSION females, 
FUSION males, Gene SMART females, Gene SMART 
males). Given that females displayed significantly higher 
type I fibre proportions than males in both cohorts, we 
could not simply include type I fibre content in a linear 
model performed on a mixed sex cohort as two issues 
would arise: (1) collinearity of fibre type with sex, (2) 
differences in fibre type proportions may be a down-
stream effect of sex. Dividing the cohorts by sex, con-
ducting a meta-analysis, and selecting the sex-biased 
DMPs and performing an FDR adjustment among those 
cites allowed us to address whether fibre type propor-
tion is associated with DNA methylation at sex-biased 
DNA methylation loci. The fibre type meta-analysis was 
performed with the same methodology of the sex meta-
analysis as described above.
Controlling for the female menstrual cycle
Various contraceptives have different dosage, administra-
tion patterns, and different hormone combinations caus-
ing variability in metabolism and gene expression [120]; 
therefore, only females not taking any form of hormo-
nal contraceptives were recruited for the Gene SMART 
study. Furthermore, to minimise the effect of fluctuating 
hormone levels, females were required to have a regu-
lar menstrual cycle (27–35  days), and all samples were 
aimed to be collected during the early follicular phase 
(day 1-day 8 of cycle), with few exceptions due to logis-
tics. Estrogen, progesterone, follicle stimulating hormone 
(FSH), and luteinizing hormone (LH) were measured in 
blood serum. Given the intricate fluctuations of the ovar-
ian hormones, these four hormones were combined into 
a principal component analysis and the first two PCs, 
which explained the majority of the variability, were each 
added into the linear model.
Blood serum hormones
The hormone assays were completed in the accredited 
pathology laboratory at Monash Health, Australia. Estra-
diol (E2) and Progesterone assays are competitive bind-
ing immunoenzymatic assays performed on the Unicel 
DXI 800 system (Beckman Coulter). FSH assay is based 
on Microparticle Enzyme Immunoassay (MEIA) and 
is carried out on the Unicel DXI 800 system (Beckman 
Coulter). The LH and sex-hormone binding globulin 
(SHBG) assays were performed using a sequential two-
step immunoenzymatic (“sandwich”) assay carried out on 
a Unicel DXI 800 (Beckman Coulter). Testosterone was 
measured using the HPLC–tandem mass spectrometry 
method using a liquid sample extraction (AB Sciex Triple 
Quad 5500 liquid chromatography–tandem mass spec-
trometry). Free androgen index was calculated as (total 
testosterone × 100)/SHBG. Free testosterone was calcu-
lated by the Södergard free testosterone calculation (36).
Integration of DNA Methylation and Gene Expression
The Genotype-Tissue Expression (GTEx) Project sex-
biased data were downloaded from the GTEx Portal 
on 08/26/2020 and filtered for skeletal muscle samples. 
The enrichment of DMG for GTEx DEGs was done by 
supplying the list of sex-biased genes to the gsameth 
function in the missMethyl R package [116, 117], which 
performs a hypergeometric test and outputs a p value 
and which genes are significant within the supplied 
list, taking into account biases due to the number of 
CpG sites per gene and the number of genes per probe 
on the EPIC array. Therefore, caution should be taken 
when interpreting the number of DMPs reported per 
DMG. The analysis for direction of correlation between 
DNA methylation and gene expression was performed 
by randomly shuffling DNA methylation effect sizes 
and performing 10,000 permutations to assess how 
often a negative correlation occurs. This analysis was 
performed for both GTEx and FUSION transcriptome 
data and yielded similar results; data presented reflect 
results from the integration of differential methyla-
tion with differential GTEx expression. Significance 
reported for GTEx sex-biased genes is represented as 
the local false sign rate (lfsr) which is analogous to FDR 
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[121]. GTEx effect sizes are represented as mash poste-
rior effect sizes [121], in which positive values indicate 
male-biased genes and negative values indicate female-
biased genes. FUSION and Gene SMART gene expres-
sion significance statistics are represented as FDR and 
p value, respectively, and effect sizes as fold changes for 
both cohorts.
Validation of top genes with qPCR
Skeletal muscle previously stored at − 80  °C was lysed 
with the RLT buffer Plus buffer (Qiagen) and beta-mer-
captoethanol using the TissueLyser II (Qiagen, Australia). 
DNA was extracted using the AllPrep DNA/RNA Mini 
Kit following the manufacturer guidelines (Qiagen, Aus-
tralia). RNA yield and purity were assessed using the 
spectrophotometer (NanoDrop One, Thermo Fisher). 
RNA was reverse transcribed to cDNA using a commer-
cially available iScript Reverse Transcriptase supermix 
(cat #1708841) and C1000 Touch Thermal Cycler (Bio-
Rad, Hercules, CA, USA). Complementary DNA samples 
were stored at − 20  °C until further analysis. Quantita-
tive real-time PCR was performed using SYBR Green 
Supermix (Bio-Rad, Hercules, CA) and gene-specific 
primers (listed in Additional file 12: Table S11). Primers 
were either adapted from existing literature or designed 
using Primer-BLAST (http:// www. ncbi. nlm. nih. gov/ 
tools/ primer- blast/) to include all splice variants, and 
were purchased from Integrated DNA Technologies. Ten 
microliter reactions comprised of SYBR, and optimized 
concentrations of forward and reverse primers (Addi-
tional file  12: Table  S11 for primer conditions), nucle-
ase-free water and 8  ng of cDNA were run in triplicate 
using an automated pipetting system (epMotion M5073, 
Eppendorf, Hamburg, Germany), with no-template 
negative controls on a 384-well plate in a thermo-cycler 
(QuantStudio 12  K Flex System, Thermo Fisher Scien-
tific, Australia). Gene expression was normalized to the 
geometric mean expression of the two most stable house-
keeping genes, as determined by Ref finder, TATAA-box 
binding protein (TPB), and 18  s rRNA, which did not 
differ between sexes (Additional file 12: Table S11). Data 
are presented as the fold change in males compared to 
females, using  2−∆∆CT.
Significance
The importance of uncovering biological sex differences 
and their translation to physiology has become increas-
ingly evident. Using a large-scale meta-analysis of three 
cohorts, we perform the first comparison of genome-wide 
skeletal muscle DNA methylation between males and 
females, and identify thousands of genes that display sex-
differential methylation. We then explore intrinsic biolog-
ical factors that may be underlying the DNA methylation 
sex differences, such as fibre type proportions and sex 
hormones. Leveraging the GTEx database, we identify 
hundreds of genes with both sex-differential expression 
and DNA methylation in skeletal muscle. We further 
confirm the sex-biased genes with gene expression data 
from two cohorts included in the methylation meta-anal-
ysis. Our study integrates genome-wide sex-biased DNA 
methylation and expression in skeletal muscle, shedding 
light on distinct sex differences in skeletal muscle.
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Additional file 4. DMRs. Differentially methylated regions between males 
and females in the meta‑analysis Stouffer, HMFDR, and Fisher <0.005. 
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Additional file 8. KEGG (DMPs). Kyoto Encyclopedia of Genes and 
Genomes pathways identified with GSEA using the differentially 
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methylated positions. Description of KEGG pathway, N represents the total 
number of genes in the KEGG pathway, DE represents the number of dif‑
ferentially methylated genes in the KEGG pathway, and SigGenesInSet are 
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Additional file 9. KEGG (DMRs). Kyoto Encyclopedia of Genes and 
Genomes pathways identified with GSEA using the differentially methyl‑
ated regions. Description of KEGG pathway, N represents the total number 
of genes in the KEGG pathway, DE represents the number of differentially 
methylated genes in the KEGG pathway, and SigGenesInSet are the dif‑
ferentially methylated genes in the KEGG pathway.
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Includes 20 females (20 at rest before four weeks of exercise training, 
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Additional file 14. Data available for each of the datasets included in 
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Additional file 15. List of transcription factors (TFs) included in analysis 
for enrichment of transcription factor binding sites (TFBSs) among differ‑
entially methylated positions (DMPs). The current UniBind database tests a 
total of 268 unique TFs from 518 different cell types.
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